Japanese

NMDA-GluR Subunit Antibody-Positive Encephalitis: A Clinical Analysis of Five Cases Chikako Kaneko 1 , Norshalena Shakespear 1 , Mario Tuchiya 1 , Jin Kubo 1 , Teiji Yamamoto 1 , Soichi Katayama 1 , Yukitoshi Takahashi 2 1Department of Neurology, Southern Tohoku Research Institute for Neuroscience 2National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorder Keyword: 抗NMDA受容体抗体脳炎 , 卵巣奇形腫 , ステロイドパルス療法 , 血漿交換療法 , 経静脈的免疫グロブリン大量療法 , anti-NMDA-receptor encephalitis , teratoma , pulse dose intravenous methylprednisolone , plasma exchange , high dose immunoglobulin pp.1099-1107
Published Date 2016/9/1
DOI https://doi.org/10.11477/mf.1416200557
  • Abstract
  • Look Inside
  • Reference

Abstract

Five consecutive cases of anti-NMDA-receptor encephalitis that we encountered were marked by a rapidly fluctuating level of consciousness associated with psychotic and delirious mental states. Opisthotonus, catatonia, and rhythmic and non-rhythmic involuntary movements of the mouth and jaw were also characteristic features of these particular cases. Serious and potentially fatal problems included epilepsia partialis continua, partial and generalized seizures, and respiratory depression, resembling the symptoms of encephalitis lethargica. An epidemic of encephalitis lethargica, also known of Economo encephalitis, occurred around 1917. Magnetic resonance imaging revealed edema of the neocortex in two cases and electroencephalography showed polymorphic and monomorphic delta slowing in the acute stage, although electroencephalographic seizure activity were not apparent. Routine cerebrospinal fluid analyses revealed lymphocyte-dominant pleocytosis in three cases, but antibodies against the NMDA-GluR subunit, GluN2B N-terminal, were at a high level in the fluid. All patients recovered without apparent sequelae. Two patients found to have ovarian teratoma underwent surgery for tumor removal. Treatments included pulse intravenous methylprednisolone, high-dose immunoglobulin, and plasma exchange together with seizure control and respiratory support. However, rituximab and or cyclophosphamide pulse therapy should also be considered for intractable cases, as indicated by recent reports.

(Received February 16, 2016; Accepted May 2, 2016; Published September 1, 2016)


Copyright © 2016, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院

関連文献

もっと見る

文献を共有